Analyst Price Target is $11.00
▲ +554.76% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for FSD Pharma in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 554.76% upside from the last price of $1.68.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in FSD Pharma.
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.